ArticleMolecular therapy. Methods & clinical development2025

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes.

Kris Poulsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.